Indeed, CCR5 and CCR2 have interrelated pharmacologies in immune signaling, particularly for the inhibitory myeloid compartment, which may overcome potential interreceptor redundancy or enable a synergistic effect in limiting COVID-19 adverse immunopathology [76–78]. This evidence concerns the gene CCR2 and COVID-19.